Details

Autor(en) / Beteiligte

• Palumbo, Antonio
• Hajek, Roman
• Delforge, Michel
• Kropff, Martin
• Petrucci, Maria Teresa
• Catalano, John
• Gisslinger, Heinz
• Wiktor-Jędrzejczak, Wiesław
• Zodelava, Mamia
• Weisel, Katja
• Cascavilla, Nicola
• Iosava, Genadi
• Cavo, Michele
• Kloczko, Janusz
• Bladé, Joan
• Beksac, Meral
• Spicka, Ivan
• Plesner, Torben
• Radke, Joergen
• Langer, Christian
• Yehuda, Dina Ben
• Corso, Alessandro
• Herbein, Lindsay
• Yu, Zhinuan
• Mei, Jay
• Jacques, Christian
• Dimopoulos, Meletios A

Titel

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2012-05, Vol.366 (19), p.1759-1769

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients treated with an induction regimen of melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance therapy had longer progression-free survival than those who did not receive maintenance therapy. Melphalan–prednisone (MP) has long been the treatment of choice for patients with multiple myeloma who are older than 65 years of age. 1 The introduction of new agents in the past few years has substantially changed the treatment of multiple myeloma. MP plus either thalidomide or bortezomib is reported to improve progression-free survival and overall survival, as compared with MP alone, 2 , 3 and these combinations are now considered the new standards of care for elderly patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation. 1 Lenalidomide in combination with dexamethasone is effective in relapsed or refractory multiple myeloma 4 – . . .